NCT00895466View on ClinicalTrials.gov

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2009

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

PEP-223/CoVaccine HT

Trial Locations (2)

9713 GZ

RECRUITING

UMC Groningen, Groningen

Unknown

RECRUITING

UMC Nijmegen, Nijmegen

Sponsors
All Listed Sponsors
collaborator

TFS Trial Form Support

INDUSTRY

lead

Pepscan Therapeutics

INDUSTRY

NCT00895466 - Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter